Clinical Research Directory
Browse clinical research sites, groups, and studies.
Butyrate-enriched Triglyceride and Diabetes Prevention
Sponsor: Maastricht University Medical Center
Summary
A body of animal studies as well as observational studies in humans demonstrated that butyrate is one SCFA that has pronounced positive effects on body weight control, inflammation, and insulin resistance. Even though the SCFA hexanoate is less researched, it has been shown to be involved in anti-inflammatory processes. Of note, acute human studies showed that fibre-induced metabolic improvements are linked to higher SCFA levels in the systemic circulation. It has been shown that a butyrate/hexanoate-enriched triglyceride oil enhanced systemic butyrate and hexanoate concentrations for a prolonged time. Yet, it remains to be determined whether a chronic increase in circulating butyrate and hexanoate concentrations translate into long-term benefits. In this study it is hypothesized that a chronic increase of butyrate/hexanoate in the circulation may improve host metabolism and metabolic health by improving adipose tissue function, reducing systemic lipid overflow and inflammation thereby increasing peripheral insulin sensitivity in individual with overweight/obesity and prediabetes.
Official title: Prevention of Diabetes with a Novel Butyrate-enriched Triglyceride
Key Details
Gender
All
Age Range
20 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2024-09-19
Completion Date
2027-09-01
Last Updated
2024-10-26
Healthy Volunteers
Yes
Conditions
Interventions
butyrate/hexanoate-enriched triglycerides
The oils are consumed two times a day for 24 weeks (six months).
Locations (1)
Maastricht University
Maastricht, Limburg, Netherlands